Understanding Tysabri and PML Risk: A Massachusetts Safety Review
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Specific Risk Assessment
If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Decades of pharmacovigilance have established a clear link between Tysabri use and PML, leading to rigorous safety monitoring protocols. This page provides a neutral, evidence-based summary of the safety review for Tysabri in Massachusetts, including current risk factors and regulatory oversight.
Understanding Tysabri and Its Association with PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri highlighting this risk. Clinical presentation and diagnosis of PML involve a range of neurological symptoms that can mimic multiple sclerosis relapses, including progressive weakness, visual disturbances, cognitive decline, and coordination difficulties. Diagnosis is confirmed through brain MRI and detection of JCV DNA in cerebrospinal fluid. The latency between Tysabri exposure and PML onset can vary, but risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML has also been reported after Tysabri discontinuation in patients without suggestive findings at the time of stopping therapy, necessitating continued monitoring for at least six months post-discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Mechanism of Action and Risk Factors
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte adhesion and migration across the blood-brain barrier, Tysabri reduces immune surveillance in the central nervous system. This immunosuppressive effect allows latent JCV, which is present in a majority of the population, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing Tysabri therapy, weighing expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adequacy of warnings regarding Tysabri and PML is a central issue in legal and settlement considerations. The FDA boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure informed prescribing and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Statute of Limitations for Tysabri PML Claims in Massachusetts
For affected patients in Massachusetts, settlement-related considerations involve the statute of limitations for filing claims. Massachusetts law generally allows three years from the date of injury or from when the injury reasonably should have been discovered for personal injury claims. Given the latency between Tysabri exposure and PML diagnosis, the discovery rule may apply, meaning the statute of limitations begins when the patient knew or should have known that PML was caused by Tysabri. This timeline can be complex, as PML symptoms may initially be attributed to multiple sclerosis or other conditions. Patients who developed PML after Tysabri therapy should consult legal counsel to determine applicable deadlines based on their specific diagnosis date and when the link to Tysabri was recognized. Settlement amounts for Tysabri-related PML cases have varied based on factors such as severity of disability, medical expenses, lost earnings, and pain and suffering. The timeline between exposure and documented harm is critical: longer treatment duration increases PML risk, and earlier diagnosis may improve outcomes, though severe disability or death remains common. Patients with anti-JCV antibodies, those treated beyond two years, and those with prior immunosuppressant use are at highest risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Documentation of these risk factors, along with MRI findings and JCV testing, is essential for establishing causation in legal claims.
Conclusion and Next Steps
In summary, Tysabri-associated PML is a serious adverse event with well-defined risk factors and clinical presentation. The FDA boxed warning and TOUCH program provide risk mitigation, but affected patients in Massachusetts must be aware of the statute of limitations for filing claims, which may be subject to the discovery rule given the latency of PML. Settlement considerations depend on individual circumstances, including the timing of diagnosis and the presence of known risk factors. Patients should seek both medical and legal guidance promptly to preserve their rights.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in Massachusetts?
Massachusetts law generally allows three years from the date of injury or from when the injury reasonably should have been discovered for personal injury claims. Given the latency between Tysabri exposure and PML diagnosis, the discovery rule may apply, meaning the statute of limitations begins when the patient knew or should have known that PML was caused by Tysabri. It is important to consult legal counsel to determine applicable deadlines based on individual circumstances.
What are the primary risk factors for developing PML while on Tysabri?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.